Clinical Trial Detail

NCT ID NCT03474640
Title Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Shanghai Junshi Bioscience Co.,Ltd.
Indications

esophageal carcinoma

endometrial cancer

sarcoma

Advanced Solid Tumor

stomach carcinoma

nasopharynx carcinoma

Therapies

Toripalimab

Age Groups: senior adult

No variant requirements are available.